Main Menu

ICR-CTSU Early Phase and Adaptive Trials

Professor Christina Yap’s team embedded within the ICR’s Clinical Trials and Statistics Unit develop and implement efficient statistical techniques in clinical trial designs and analyses, with the ultimate aim to get new drugs safely, effectively, and as quickly as possible to the patients for whom they can be life-changing.

Team leader

Professor Christina Yap

Professor Christina Yap

Team Leader

Christina Yap is Professor of Clinical Trials Biostatistics at the ICR’s Clinical Trials and Statistics Unit. Christina is an expert in the design and implementation of efficient, adaptive designs in clinical trials.

ORCID 0000-0002-6715-2514

Team members

Dr Xiaoran Lai
Dr Xiaoran Lai
Senior Statistician

Xiaoran received his PhD in Biostatistics from University of Oslo in Norway, where he developed a mathematical model to simulate breast cancer treatment using multi-type patient data. He is interested in integrating multi-scale cancer data using mechanistic models and machine learning techniques in order to provide precise therapeutic recommendations as well as novel clinical study designs and interventions.

Dr Pavel Mozgunov
Dr Pavel Mozgunov
Honorary Research Visitor

Pavel Mozgunov is an NIHR Advanced Fellow working on the development and implementation of adaptive designs in clinical trials. His main areas of research are dose-finding designs for Phase I trials and designs for Phase II. Pavel provides statistical support in several early and late trials both publicly and privately funded.

Dr Jan Rekowski
Dr Jan Rekowski
Senior Statistician

Being educated in Munich and Dortmund Jan graduated in statistics. An internship with Novartis in Basel was followed by a position as research associate and trial statistician at the University Hospital Essen. After obtaining his PhD he joined the ICR in 2020, where he works on clinical trials at ICR-CTSU and developed a focus on translational medicine.

Mahtab Rouhi
Mahtab Rouhi
Trial Statistician

Mahtab is educated in Biostatistics. Based on her experience, she is qualified in clinical research area including clinical trial studies. She joined ICR in 2022 as a Trial Statistician focusing on analysis of several clinical trials within the ICR/Royal Marsden Drug Development Units early phase trials. Mahtab is also interested in developing and implementing efficient trial methodology in early phase and adaptive trials.

Dr Olga Solovyeva
Dr Olga Solovyeva
Trial Methodologist

Having substantial experience in corporate management and finance, Olga has turned her career towards clinical studies joining the ICR in 2021 for the development of consolidated standards of reporting trials (CONSORT) for early phase dose-finding trials. Outside of work, Olga enjoys spending time with her daughter. Their Akita-dog joins them on every possible occasion.​

Zhulin Yin
Zhulin Yin
PhD student

Zhulin is a PhD student in the Clinical Trials and Statistics Unit. Her main research interest is on early phase clinical trial designs, data analysis and systematic review. The project title of her PhD is “Development and Implementation of Efficient Adaptive Designs in Early Phase Oncology Trials for Targeted Agents”.

Yuqi Zhang
Yuqi Zhang
Summer Research Student

Yuqi is a summer student at ICR-CTSU. Meanwhile, he is an upcoming fourth-year mathematics and statistics student at the University of Oxford. His main research interest lies in Bayesian Inference and Computational Statistics, especially their applications in medical research and clinical trial design. Yuqi is currently working on the analysis of Estimands framework in protocols, SAPs, and reports of oncology early phase dose-finding trials this summer.

Dr Haiyan Zheng
Dr Haiyan Zheng
Honorary Appointment

Haiyan Zheng is a CRUK PRC Fellow passionate about efficient design and analysis of clinical trials. She currently leads a three-year research programme to develop statistical methods that (1) simultaneously evaluate treatment effects in multiple subgroups, and (2) allow for mid-course adaptations in master protocol trials.

Emily Alger
PhD Student
Aude Espinasse
Clinical Trials Programme Manager